

# **Thailand Morning Cuppa – Mid-Morning Edition**

This report is an update of the "Thailand Morning Cuppa" we provided earlier today.

# **Story Update**

Bangkok Chain Hospital (BCH TB, BUY, TP: THB30.50)

Reaching a Further High In 3Q; Still BUY

Company Update

Still BUY and DCF-based THB30.50 TP, 34% upside and c.2% yield. Bangkok Chain Hospital's 2H21 outlook remains optimistic, as 3Q21 earnings may strongly increase to another high while pent-up demand for non-COVID-19 treatments and higher vaccination could support 4Q21 and strengthen organic growth in 2022 vs 2020. Valuation looks undemanding

Analyst: Vatcharut Vacharawongsith +66 2088 9736

Today's Report: <u>Bangkok Chain Hospital : Reaching a Further High In 3Q; Still BUY</u> (27 Aug 2021) Previous Report: <u>Bangkok Chain Hospital : Riding On Solid 2Q-3Q Outlook; U/G To BUY</u> (19 Jul 2021)




Table 1: Key market indices (27 Aug 2021)

	Index	Chg	% Chg
SET	1601.91	+1.42	+0.09
SET50	964.79	-0.66	-0.07
SET100	2195.59	-1.20	-0.05
Dow Jones	35213.12	-192.38	-0.54
Nasdaq	14945.81	-96.05	-0.64
S&P500	4470.00	-26.19	-0.58
FTSE	7124.98	-25.14	-0.35
FSSTI	3109.42	+1.93	+0.06
Hang Seng	25415.69	-278.26	-1.08
Nikkei	27742.29	+17.49	+0.06
KLCI	1585.74	+15.94	+1.02
SHANGHAI SE	3501.66	-38.72	-1.09
JCI	6058.08	-55.16	-0.90

Note: \*As at 26 Aug 2021 closing





# Bulletin

# STOCK/SECTOR NEWS

## Real Estate

AP (Thailand) (AP TB)

Supalai (SPALI TB) According to Knight Frank Thailand's research data, the condominium (condo) market in 1H21 continued to shrink vis-à-vis 2H20 Maior

continued to shrink vis-à-vis 2H20. Major property developers have to postpone or delay the launch of new condo projects to 4Q21 while focusing on low-rise developments to serve buyers with real demand for housing.

The cumulative supply of condos in Bangkok stood at 652,081 units in 1H21 (-38.7% YoY), with 6,293 units from 20 projects launched in 1H21. The number of new condos launched in Bangkok suburbs accounted for 66% of the total new supply launched during this period, while city fringe and central business district (CBD) areas accounted for 29% and 5%. Of the 6,293 units in new supply, only 2,333 units were sold in 1H21 and represented an absorption rate of 37.1%. The selling price of condos in the CBD was THB240,609 per sq m (-4.3% HoH). Condos in city fringe areas were at THB116,225 per sq m (-5.9% HoH) while condos in suburban Bangkok stood at THB64,390 per sq m (-6.6% HoH).

In 1H21, the listed companies have turned their focus on developments in the low-rise market for single-detached houses, duplexes, and townhouses. The work-from-home trend has been driven by the emergence of necessity. There were 224 housing projects available for sale with a total 20,018 units. Approximately 13.276 units were sold, and this represented an absorption rate of 66%. Houses with the highest demand were priced between THB10m and THB20m, with cumulative sales of 7,218 units (61% absorption rate) while THB21-30m and THB31-40m units were sold at 2,612 units (77% absorption rate) and 1,871 units (73% absorption rate). The number of new units sold in 1H21 was 1.610 units, indicating that the number of new units sold was guite high when compared to previous years, with an average number of new units sold at only 2,500 units per year (Bangkokbiznews)

# COMMENT

Clearly, the condo market in Bangkok remains in the doldrums in 1H21. However, the tough market situation has eased off, given slower new supply launches by developers and a slightly better absorption rate. Although developers launched new condo projects with lower selling prices in all sub-locations in Bangkok, a 37.1% absorption rate in the city's condo market is considered a low level in our view. This should improve further in case developers remain cautious in launching new condo projects.

In comparison, low-rise projects – especially with unit prices of more than THB10m – were in good shape. Absorption rates were high among unit prices in the range between THB10m and THB40m, while the selling rate in low-rise project segment remained speedy in 1H21. This implied that the solid demand in this segment is evident and will continue to be consistent in 2H21.

Therefore, we maintain our optimistic view over major low-rise project developers in Thailand, especially ones that have shown consistent records in boosting their low-rise project presales since FY20. Our Top picks include AP (Thailand) (AP) and Supalai (SPALI). We maintain our call on the sector while retaining our recommendations and TPs for the two stocks.

# RATING

#### Sector: NEUTRAL

27 August 2021

Stocks: AP BUY, TP: THB9.50

SPALI: BUY, TP: THB23.60

**Thailand** Daily



# Thailand Daily 27 August 2021

Top BUYs					
	TP	Upside	Catalysts		
Airports of Thailand (AOT TB)	( <b>THB</b> ) 73.50	<b>(%)</b> 17.60	<ul> <li>3QFY21 (Sep) is likely the weakest quarter, as domestic aviation has led AOT's performance and the severe COVID-19 third wave may dampen local tourism activities. Cost optimisation efforts have been implemented effectively since 3QFY20, but variable expenses rose in tandem with a recovery in aeronautical activities post lockdown</li> <li>Regarding the Government's border re-opening scheme from Jul 2021 onwards, we expect some positive sentiment on the Phuket Sandbox Model towards AOT, as Phuket International Airport is its third-largest property</li> <li>As the first-tier tourism player, AOT may strongly underpin the revival of the tourism industry, while the weakening short-term sentiment and earnings present investors with an opportunity to BUY</li> </ul>		
Home Product Center (HMPRO TB)	16.40	17.99	<ul> <li>Expecting normalising earnings in FY21 – to be supported by full-year operations of all stores and retail malls vs a temporary closure from late March to mid-May, with profit margins approaching pre-pandemic levels</li> <li>HMPRO's investment in Vietnam may strongly benefit growing urbanisation and a potential rise in the construction sector</li> <li>Quarterly earnings momentum will continue its upward trajectory in 1Q21</li> <li>Rapid improvement in sustainability development may allow the stock to continue trading at a premium</li> </ul>		
Kasikornbank (KBANK TB)	150.00	25.52	<ul> <li>One of opening theme plays, given the highest exposure to the small &amp; medium enterprise or SME portion among the banks we cover or TH Banks</li> <li>Investors should look forward to an eventual recovery, as the recovery in the short term is likely to be uneven and take time before reaching pre-COVID-19 levels</li> <li>The bank trends to disrupt itself with new technologies. We believe this strategy will help the bank to improve profitability and quality in the long run</li> <li>FY21F earnings outlook is forecasted to rebound 8.5% in line with sector earnings. This is due to lower provisions and a rebound in net fees income</li> <li>Our valuation is conservative and its share price is trading below -1SD from the historical mean, which is compelling</li> </ul>		
PTT Exploration & Production (PTTEP TB)	132.00	23.36	<ul> <li>We like PTTEP as a good proxy to stronger commodity prices</li> <li>2Q21 earnings are expected to register stronger results on the back of stronger sales volumes and crude prices</li> </ul>		
PTT Global Chemical (PTTGC TB)	73.00	17.74	<ul> <li>Bumper 1H21 earnings expected from robust petrochemical product spreads to translate into a strong FY21F rebound in YoY performance</li> <li>Current uptrend in oil prices also expected to see PTTGC regain its gas-based crackers' relative cost advantage over industry peers operating naphtha-based crackers</li> </ul>		
Siam Cement (SCC TB)	500.00	17.37	<ul> <li>Petrochemicals is currently in an upcycle. HDPE-naphtha spread in 1Q21 should remain as high as levels recorded in 4Q20, while the polypropylene-naphtha spread reached another high in 1Q21. SCC's polyolefin sales volumes returned to normal levels after the turnaround of the Map Ta Phut olefin cracker was completed in 4Q20</li> <li>The improvement in cement &amp; building materials business should be noticeable in 1Q21, with cement demand growing 1-2% in Thailand. This would be due to stronger demand from the residential property sector in provincial areas, and continuously solid demand stemming from government infrastructure projects</li> <li>FY21 will start out with strong earnings growth in 1Q21, while the petrochemical division may be driven by higher production volume after de-bottlenecking the Map Ta Phut olefin cracker finishing 2Q21. For 2H21, we expect a brighter outlook for the cement &amp; building materials business especially in ASEAN, when construction activities resume to normal</li> </ul>		
Tisco Financial (TISCO TB)	111.00	18.40	<ul> <li>Superior asset quality to peers and strong capital base – highest among TH Banks – made TISCO deserve to trade at premium valuation.</li> <li>Its c.7% dividend yield is compelling and relatively highest among TH Banks, with full-year payment basis.</li> <li>We believe TISCO's conservative strategy amidst the pandemic will be proper, allowing the bank to survive post COVID-19</li> <li>FY21 earnings is expected to rebound 7%YoY mainly on lower provisions and a rebound in net fees income, despite moderated NII and a slight increase in overheads</li> </ul>		





# **Recent Stories**

To access the following reports, please click on the link: <u>RHB | Thailand Morning Cuppa : 26 August 2021</u> PTT Exploration & Production : Demand On a Recovery Path; Keep BUY

RHB | Thailand Morning Cuppa : 25 August 2021 TOA Paint : Another Hurdle In 3Q21; Maintain SELL

RHB | Thailand Morning Cuppa : 24 August 2021 Berli Jucker : Outlook Still Attractive; D/G To NEUTRAL

<u>RHB | Thailand Morning Cuppa : 23 August 2021</u> <u>Banks : Additional Measures To Help</u> CH Karnchang : Countdown To Another New Job; Keep BUY

RHB | Thailand Morning Cuppa : 20 August 2021 Electric Vehicles : The Future Is EV. Is ASEAN Ready?

RHB | Thailand Morning Cuppa : 19 August 2021 Charoen Pokphand Foods : Long-Term Sustainable Post-Pandemic Player

RHB | Thailand Morning Cuppa : 18 August 2021 Mega Lifesciences : Strong 2H Outlook Continues; Reiterate BUY

RHB | Thailand Morning Cuppa : 17 August 2021 Ratch Group : Bearing With The Dilution Effect; D/G To NEUTRAL

<u>RHB | Thailand Morning Cuppa : 16 August 2021</u> <u>Osotspa : Seeking Margins-Driven Profits In 2H; Keep BUY</u> <u>2H21 Growth Outlook Dims As Virus Spreads</u>

 RHB | Thailand Morning Cuppa : 13 August 2021

 RHB | Thailand Morning Cuppa : 13 August 2021 Mid-Morning Edition

 CP ALL : Short-Term Pressures; Still BUY

 PTT Oil and Retail Business : Sturdy Player With Long-Term Opportunities; BUY

 PTT : A Decent Quarter; Keep BUY

 Muangthai Capital : Risks Persist, Yet Manageable; Stay BUY

 Thai Union Group : Demand Grows On US, EU Recovery; Keep BUY

 Land and Houses : Moderately Strong Player; Maintain BUY

 RHB | Thailand Morning Cuppa : 11 August 2021

 RHB | Thailand Morning Cuppa : 11 August 2021 - Mid Morning Edition

 IRPC : Favourable Product Mix; Upgrade To BUY

 Thai Oil : Unexpectedly Weak 2Q21; D/G NEUTRAL

 AP (Thailand) : Cool Under Pressure; Still BUY

RHB | Thailand Morning Cuppa : 10 August 2021 Central Pattana : Challenged By The Pandemic; Keep BUY PTT Global Chemical : A Bumper 1H21; Keep BUY Sermsang Power : Small Size, Big Potential For Growth

<u>RHB | Thailand Morning Cuppa : 9 August 2021</u> Global Power Synergy : Right Time, Right Directions

RHB | Thailand Morning Cuppa : 6 August 2021 Home Product Center : Sluggish 3Q, Seeking a 4Q Rebound; Keep BUY

RHB | Thailand Morning Cuppa : 5 August 2021 Industrial Estate : Dimmer Outlook Ahead

RHB | Thailand Morning Cuppa : 4 August 2021 Advanced Info Service : Renewed Pandemic Headwinds; Maintain BUY Policy Rate Will Remain At 0.5% In 2H21

RHB | Thailand Morning Cuppa : 3 August 2021 Banks : Pre-COVID-19 ROE a Distance Dream; Downgrade





#### **RHB Guide to Investment Ratings**

 Buy:
 Share price may exceed 10% over the next 12 months

 Trading Buy:
 Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain

 Neutral:
 Share price may fall within the range of +/- 10% over the next 12 months

 Take Profit:
 Target price has been attained. Look to accumulate at lower levels

 Sell:
 Share price may fall by more than 10% over the next 12 months

 Not Rated:
 Stock is not within regular research coverage

#### **Investment Research Disclaimers**

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions.





Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated event

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

## **RESTRICTIONS ON DISTRIBUTION**

## Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Bhd. The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHB Investment Bank Bhd has no obligation to update its opinion or the information in this report.

## Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.





#### Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

#### Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (Singapore branch) which is a holder of a full bank licence and an exempt capital markets services licence and financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (Singapore branch) in respect of any matter arising from or in connection with the report.

#### **United States**

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

Please refer to the following link (<u>RHB Research conflict disclosures – Aug 2021a</u>) and the Disclosure of Conflict of Interest in each of the research reports provided in this email for more details.

Kuala Lumpur
RHB Investment Bank Bhd
Level 3A, Tower One, RHB Centre
Jalan Tun Razak
Kuala Lumpur
Malaysia
Tel : +(60) 3 9280 8888
Fax : +(60) 3 9200 2216

### Jakarta

PT RHB Sekuritas Indonesia Revenue Tower, 11th Floor, District 8 - SCBD JI. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia Tel : +6221 509 39 888 Fax : +6221 509 39 777 Singapore RHB Bank Berhad (Singapore branch) 90 Cecil Street #04-00 RHB Bank Building Singapore 069531

#### Bangkok

RHB Securities (Thailand) PCL 10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand Tel : +(66) 2 088 9999 Fax : +(66) 2 088 9799

